Tumor suppressor CAR-1

Details Tumor suppressor CAR-1 Tumor suppressor CAR-1

2005-09-13

2005-09-13

Priebe, Scott D. (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C536S024100, C536S024200, C536S024310, C536S024300, C435S320100, C435S325000, C435S455000, C435S471000, C435S357000, C435S365000, C435S367000, C435S370000, C435S243000, C435S252300

Reexamination Certificate

active

06943245

ABSTRACT:
The present invention relates to a new tumor suppressor, designated CAR-1, the gene for which is located on the short arm of human chromosome 1. This gene is directly implicated in colon, kidney and breast cancers, and the CAR-1 ubiquitous expression of the corresponding transcript suggests that it may be involved in yet others. Thus, one aspect of the invention is the diagnosis of CAR-1-related malignancies. The full length cDNA for CAR-1, as well as oligonucleotides derived therefrom, are disclosed. Screening methods for modulators of CAR-1 function and expression, as well as methods for cancer therapy, are described.

REFERENCES:
patent: 5872237 (1999-02-01), Feder et al.
patent: 6312926 (2001-11-01), Shatkin et al.
patent: 2002/0048763 (2002-04-01), Penn et al.
patent: 2002/0198371 (2002-12-01), Wang et al.
patent: 1 074 617 (2001-02-01), None
patent: WO 98/42739 (1998-10-01), None
patent: WO 01 57182 (2001-09-01), None
Hillier et al. (GenBank Accession No. R71654, US National Library of Medicine, Bethesda, MD, Jun. 1995, accessed by PTO on Sep. 21, 2004.
Waterson, Genbank Accession No. AC022262, US National Library of Medicine, Bethesda, MD, Jul. 2000, accessed by PTO on Oct. 23, 2003.
Ngo et al., in The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al (ed.), Birkhauser. Boston, MA, pp 433 and 492-495.
Attwood, T, Science, vol. 290, No. 5491, pp. 471-473, 2000.
Gerhold et al., BioEssays, vol. 18, No. 12, pp. 973-981, 1996.
Baker et al., Science, 294:pp. 93-96, 2001.
Russell et al., Journal of Molecular Biology, vol. 244, pp 332-350, 1994.
Wells et al., Journal of Leukocyte Biology, vol. 61, No. 5, pp. 545-550, 1997.
Wallace et al., Methods Enzymol. 152:432-443, 1987.
Sambrook et al., Molecular Cloning, A Laboratory Manual, Second Edition, 1989, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, p. 11.47.
Avela et al., “Gene encoding a new RING-B-box-Coiled-coil protein is mutated in mulibrey nanism,”Nature Genetics,25:298-301, 2000.
Bieche et al., “Deletion mapping in breast tumor cell lines point to two distinct tumor-suppressor genes in the 1p32-ter region, one of deleted regions (1p36.2) being located within the consensus region of LOH in neuroblastoma,”Oncology Reports,5:167-172, 1998.
Bieche et al., “Two distinct regions involved in 1p deletion in human primary breast cancer,”Cancer Research,53:1990-1994, 1993.
Bomme et al., “Clonal karyotypic abnormalities in colorectal adenomas: clues to the early genetic events in the adenoma-carcinoma sequence,”Genes, Chromosomes and Cancer,10:190-196, 1994.
Borden, “RING domains: master builders of molecular scaffolds?”J. Mol. Biol.,295:1103-1112, 2000.
Borg et al., “Chromosome 1 alterations in breast cancer: alleic loss on 1p and 1q is related to lymphogenic metastases and poor prognosis,”Genes, Chromosomes, and Cancer,5:311-320, 1992.
Couch et al., “Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene: Breast Cancer Information Care,”Human Mutation,8:8-18, 1996.
Cox et al., “New mutations in MID1 provide support for loss of function as the cause of X-linked Opitz syndrome,”Human Molecular Genetics,9(17):2553-2562, 2000.
Di Vinci et al., “Deletions at chromosome 1p by fluorescence in situ hybrization are an early event in human colorectal tumorigenesis,”Gastroenterology,111:102-107, 1996.
Han et al., “Infrequent somatic mutations of the p73 gene in various human cancers,”Euro. J. Surgical Oncology,25:194-198, 1999.
Ichimiya et al., “p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent,”Oncogene,18:1061-1066, 1999.
Isomura et al., “RFP is a DNA binding protein associated with the nuclear matrix,”Nucleic Acids Res.,20:5305-5310, 1992.
Kovacs et al., “Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma,”Proc. Nat'l Acad. Sci. USA,85:1571-1575, 1988.
Le Douarin et al., “The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18,”EMBO J.,14:2020-2033, 1995.
Lee et al., “The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity,”Nature,329:642-645, 1987.
Lo Cunsolo et al., “Neuroblastoma on two siblings supports the role of 1p36 deletion in tumor development,”Cancer, Genetics,&Cytogenetics,109:126-130, 1999.
Lott et al., “Physical and functional mapping of a tumor suppressor locus for renal cell carcinoma within chromosome 3p12,”Cancer Research,58:3533-3537, 1998.
Matsuzaki et al., “Detailed deletion mapping on chromosome 1p32-p36 in human colorectal cancer: Identification of three distinct regions of common allelic loss,”Int. J. Oncology,13:1229-1233, 1998.
Miki et al., “A strong candidate for the breast and ovarian-cancer suceptibility gene BRCA1,”Science,266:66-71, 1994.
Millikan et al., “Linkage analysis and loss of heterozygosity for chromosome Arm 1p in familial breast cancer,”Genes, Chromosomes, and Cancer,25:354-361, 1999.
Ogunbiyi et al., “Prognostic value of chormosome 1p allelic loss in colon cancer,”Gastroenterology,113:761-766, 1997.
Pandolfi, PML, PLZF, and NPM genes in the molecular pathogenesis of acute promyelocytic leukemia,Haematologica,81:742-482, 1996.
Ragnarsson et al., “Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival,”British J. of Cancer,79:1468-1474, 1999.
Rasio et al., “Characterization of the human homologue of RAD54: a gene located on chromosome 1p32 at a region of high loss of heterozygousity in breast tumors,”Cancer Research,57:2378-2383, 1997.
Sanchez et al., “A tumor suppressor locus within 3p14-p12 mediates rapid cell death of renal cell carcinom in vivo.,”Proc. Nat'l Acad. Sci.,91:3383-3387, 1994.
Saurin et al., “Does this have a familiar RING?”TIBS,21:208-214, 1996.
Shimono et al., “RET finger protein is a transcriptional repressor and interacts with enhancer of polycomb that has dual transcriptional functions,”J. Biol. Chem.,275(50):39411-39419, 2000.
Steck et al., “Identification of a candidate tumour suprressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers,”Nature Genetics,15:356-362, 1997.
Szabo and King, “Inherited breast and ovarian cancer,”Human Molecular Genetics,4:1811-1817, 1995.
Tanaka et al., “Suppression of tumorigenicity in human colon carcinoma cells by introduction of normal chromosome 1p36 region,”Oncogene,8:2253-2258, 1993.
Tsukamato et al., “Allelic loss on chromosome 1p is associated with progression and lymph node metastasis of primary breast carcinoma,”Cancer,82:317-322, 1998.
Vogelstein, “Cancer. A deadly inheritance,”Nature.348:681-682, 1990.
Weinberg, “Positive and negative controls on cell growth,”Biochemistry,28:8263-8269, 1989.
Wu et al., “Identification of A RING protein that can interact in vivo with the BRCA1 gene product,”Nature Genetics,14:430-440, 1996.
EMBL Database Accession No. AK001621, Feb. 22, 2000.
EMBL Database Accession No. BE258134, Jul. 14, 2000.
Lovell et al., The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment and VHL mutation,Cancer Research,59: 2182-2189, 1999.
McCluskey et al., “Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity,”Bioorganic&Medicinal Chemistry Letters,10:1687-1690, 2000.

Affiliated with

Also associated with

Rating

Tumor suppressor CAR-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor suppressor CAR-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor suppressor CAR-1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3372893